RIGEL PHARMACEUTICALS, INC. (RIGL) Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value · Debt Securities, Available-for-sale, Current · Available-for-sale Securities, Current · Accounts Receivable, after Allowance for Credit Loss, Current |
| Current obligations | 95.59M USD | Liabilities, Current |
| Cash and equivalents | 60.82M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | Debt Securities, Available-for-sale, Current · Available-for-sale Securities, Current |
| Customer receivables | 56.04M USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory · excluded from quick assets | 14.37M USD | Inventory, Net |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $95.59M | $60.82M | (m) | $56.04M | $14.37M | (m) |
| 2026-03-31 | (m) | $89.49M | $24.41M | (m) | $49.95M | $11.65M | (m) |
| 2025-12-31 | (m) | $99.24M | $40.58M | (m) | $51.76M | $11.51M | (m) |
| 2025-09-30 | (m) | $94.40M | $48.53M | (m) | $45.92M | $13.30M | (m) |
| 2025-06-30 | (m) | $86.64M | $53.41M | (m) | $39.91M | $10.42M | (m) |
| 2025-03-31 | (m) | $66.63M | $45.73M | (m) | $41.55M | $4.66M | (m) |
| 2024-12-31 | (m) | $63.30M | $56.75M | (m) | $41.62M | $6.00M | (m) |
| 2024-09-30 | (m) | $54.31M | $51.69M | (m) | $30.57M | $4.78M | (m) |
| 2024-06-30 | (m) | $58.65M | $36.05M | (m) | $28.90M | $8.06M | (m) |
| 2024-03-31 | (m) | $73.20M | $25.57M | (m) | $27.51M | $6.58M | (m) |
| 2023-12-31 | (m) | $53.27M | $32.79M | (m) | $30.55M | $5.52M | (m) |
| 2023-09-30 | (m) | $48.27M | $45.41M | (m) | $23.55M | $6.11M | (m) |
| 2023-06-30 | (m) | $44.02M | $48.81M | (m) | $20.82M | $10.78M | (m) |
| 2023-03-31 | (m) | $45.52M | $40.28M | (m) | $29.37M | $11.08M | (m) |
| 2022-12-31 | (m) | $65.21M | $24.46M | (m) | $40.32M | $9.12M | (m) |
| 2022-09-30 | (m) | $47.27M | $29.87M | (m) | $15.53M | $7.12M | (m) |
| 2022-06-30 | (m) | $54.95M | $27.20M | (m) | $17.20M | $6.22M | (m) |
| 2022-03-31 | (m) | $59.23M | $24.68M | (m) | $15.24M | $6.76M | (m) |
| 2021-12-31 | (m) | $63.55M | $18.89M | (m) | $15.47M | $6.62M | (m) |
| 2021-09-30 | (m) | $59.28M | $30.40M | (m) | $14.99M | $7.04M | (m) |
| 2021-06-30 | (m) | $59.54M | $84.82M | (m) | $17.37M | $6.83M | (m) |
| 2021-03-31 | (m) | $52.02M | $20.05M | (m) | $142.19M | $6.95M | (m) |
| 2020-12-31 | (m) | $40.84M | $30.37M | (m) | $15.97M | $1.64M | (m) |
| 2020-09-30 | (m) | $34.19M | $36.57M | (m) | $14.63M | $2.05M | (m) |
| 2020-06-30 | (m) | $34.76M | $36.47M | (m) | $11.73M | $1.68M | (m) |
| 2020-03-31 | (m) | $31.17M | $45.23M | (m) | $9.66M | $1.62M | (m) |
| 2019-12-31 | (m) | $58.21M | $22.52M | (m) | $10.11M | $1.35M | (m) |
| 2019-09-30 | (m) | $31.01M | $39.09M | (m) | $11.55M | $1.18M | (m) |
| 2019-06-30 | (m) | $28.38M | $44.23M | (m) | $6.93M | $1.22M | (m) |
| 2019-03-31 | (m) | $26.14M | $74.70M | (m) | $5.61M | $1.13M | (m) |
| 2018-12-31 | (m) | $27.73M | $76.32M | (m) | $4.08M | $894.00K | (m) |
| 2018-09-30 | (m) | $19.70M | $61.49M | (m) | $3.27M | $534.00K | (m) |
| 2018-06-30 | (m) | $17.36M | $65.08M | (m) | $1.62M | $494.00K | (m) |
| 2018-03-31 | (m) | $18.79M | $40.13M | (m) | (m) | (m) | (m) |
| 2017-12-31 | (m) | $18.34M | $38.29M | (m) | $0.00 | (m) | (m) |
| 2017-09-30 | (m) | $15.01M | $25.88M | (m) | (m) | (m) | (m) |
| 2017-06-30 | (m) | $15.87M | $32.59M | (m) | (m) | (m) | (m) |
| 2017-03-31 | (m) | $17.25M | $40.14M | (m) | (m) | (m) | (m) |
| 2016-12-31 | (m) | $22.59M | $17.63M | (m) | $0.00 | (m) | (m) |
| 2016-09-30 | (m) | $20.63M | $25.95M | (m) | (m) | (m) | (m) |
| 2016-06-30 | (m) | $22.00M | $24.95M | (m) | $95.00K | (m) | (m) |
| 2016-03-31 | (m) | $27.71M | $14.27M | (m) | $195.00K | (m) | (m) |
| 2015-12-31 | (m) | $33.80M | $43.46M | (m) | $203.00K | (m) | (m) |
| 2015-09-30 | (m) | $34.84M | $38.58M | (m) | $163.00K | (m) | (m) |
| 2015-06-30 | (m) | $34.17M | $17.29M | (m) | $350.00K | (m) | (m) |
| 2015-03-31 | (m) | $34.35M | $42.72M | (m) | $106.00K | (m) | (m) |
| 2014-12-31 | (m) | $14.03M | $15.20M | (m) | $5.75M | (m) | (m) |
| 2014-09-30 | (m) | $10.20M | $12.81M | (m) | (m) | (m) | (m) |
| 2014-06-30 | (m) | $10.06M | $23.88M | (m) | (m) | (m) | (m) |
| 2014-03-31 | (m) | $7.87M | $14.91M | $180.47M | (m) | (m) | (m) |
| 2013-12-31 | $217.72M | $10.29M | $20.85M | $191.12M | $5.75M | (m) | 21.15× |
| 2013-09-30 | (m) | $8.30M | $16.03M | $214.85M | (m) | (m) | (m) |
| 2013-06-30 | (m) | $8.47M | $21.87M | $229.77M | (m) | (m) | (m) |
| 2013-03-31 | (m) | $9.16M | $34.16M | $238.29M | (m) | (m) | (m) |
| 2012-12-31 | (m) | $12.20M | $33.48M | $264.76M | (m) | (m) | (m) |
| 2012-09-30 | (m) | $10.59M | $26.80M | $157.09M | (m) | (m) | (m) |
| 2012-06-30 | (m) | $9.50M | $26.15M | $176.49M | (m) | (m) | (m) |
| 2012-03-31 | (m) | $8.04M | $22.03M | $201.27M | (m) | (m) | (m) |
| 2011-12-31 | (m) | $11.53M | $18.63M | $229.01M | (m) | (m) | (m) |
| 2011-09-30 | (m) | $8.42M | $18.68M | $247.00M | (m) | (m) | (m) |
| 2011-06-30 | (m) | $7.79M | $42.95M | $236.15M | (m) | (m) | (m) |
| 2011-03-31 | (m) | (m) | $25.71M | (m) | (m) | (m) | (m) |
| 2010-12-31 | (m) | $11.33M | $8.88M | $168.42M | (m) | (m) | (m) |
| 2010-09-30 | (m) | (m) | $22.06M | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | $32.23M | (m) | (m) | (m) | (m) |
| 2009-12-31 | (m) | (m) | $14.72M | (m) | (m) | (m) | (m) |
| 2008-12-31 | (m) | (m) | $46.01M | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 |